Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
How much in USD with tax and shipping for 120g of EPA? TIA.
"17 years"? It takes doctors much longer time to adapt and adopt, longer than other professions such as teachers, mechanics, postal workers, DMV employees, etc.
There is a reason why there's no innovation in treating CVD for the last few decades --- because treating CVD is not a good business, which requires big investment with little in return, to get into.
JL said "V will sell itself", not JT.
L, we have concluded in previous posts that "late breaker" has no implication to the success/failure of a trial.
It just confirms your theory of near-term generic supply constraint.
KM's new marketing strategy working?
The $6.4B question is whether the US operation can be sustained long enough to fund the EU operation before it gains traction. The market say no while I bet yes.
"how a company can successfully complete a really detailed time consuming study"? Think along the line of a below average student (JT and his management team) copied the homework from his top student friends (Dr. Bhatt, Mochida and Jelis) and got an A in the homework assignment (REDUCE-IT trial). However, when the teacher (Du) asked him to explain how he solved the homework problems, he couldn't (defend the patents).
Presented conference in Berlin: “New therapeutic strategies for residual CVrisk management:
Maybe #vazkepa received marketing authorization from the European Commission in March 2021 and the Medicines and Healthcare Products Regulatory Agency (MHRA) in UK April 2021.
— May's Financial Options (@MayOptions) October 26, 2021
Presented conference in Berlin: “New therapeutic strategies for residual CVrisk management pic.twitter.com/LdG4xSCWu7
It's easy. Du being a lazy judge that she is, just copy USPTO's way of handling the MARINE patents and add her own spin saying USPTO did not consider Kura, hence invalidating the MARINE patents.
"JT, while he was still CEO of Amarin, did make a token contribution to EPADI to help fund Marjac's pursuance of the rule 60 case"? Are you sure? I thought that was a joke.
Merck is on the hunt for more deals:
https://endpts.com/ahead-of-closing-11-5b-acceleron-buyout-merck-is-on-the-hunt-for-more-deals/
Du negating the unexpected benefit of ApoB reduction by saying USPTO did not consider Kura which is false and Covington did not catch that until it's too late.
d, the patent was ultimately approved not due to Mori but due to secondary considerations of unexpected ApoB reduction (Kura), so I think Covington/Kennedy might have committed legal malpractice by arguing for the 2-patient population theory of Mori. I could see Du being lazy and copy USPTO's opinion and tossed the 2-patient population theory out the window no matter how well Covington argued for it. On hindsight, Covington should use the USPTO as a playbook and defend the unexpected benefit of ApoB reduction at all cost, hence able to discover the cropped table of Kura, etc.
mrmain, your 12 month price traget is only $6.18 so even you are not expecting a PFE BO, enough said.
It's Oct 12, 2021. An article can't be dated for a future date.
Not true, Teva asks Fed Circ for ‘skinny label’ redo:
https://www.lifesciencesipreview.com/news/teva-asks-fed-circ-for-skinny-label-redo-4601
ralph, does this count:
"10.31 In patients with atherosclerotic cardiovascular disease or other cardiovascular risk factors on a statin with controlled LDL cholesterol but elevated triglycerides (135–499 mg/dL), the addition of icosapent ethyl can be considered to reduce cardiovascular risk."
https://care.diabetesjournals.org/content/44/Supplement_1/S125
To make everybody feel better, look at ESPR's, a cohort of AMRN, YTD stock chart.
marjac, ambulance chasers should have come out shortly after 3/30/2020 to "fish" for lead plaintiff, instead, they wait till now. The timing is just off compared with other ambulance chasers cases that I have seen.
Why didn't ambulance chasers show up last year instead of now?
raf, thanks for the following good news:
"Cantor Fitzgerald has estimated the European market for the drug is $1.1 billion. Leerink pegs Europe, Canada and China as a combined $2 billion opportunity."
Where is the link for $155M? Below is the $160M link:
https://investorshub.advfn.com/uimage/uploads/2021/10/8/bcjyxCHART_4_NET_SALES_REVENUE_PER_QTR.PNG
Revenue ESTIMATE includes everything.
No, around $160M for Q3 revenue.
It's PFE or nothing as NVS and MRK have already made their purchases. You can have my CVR since I don't expect any.
Kiwi, let KM put the EVAPORATE data to good use then.
Though not a done deal, seems legit:
https://www.fiercepharma.com/pharma/bristol-myers-squibb-after-passing-acceleron-now-eyes-aurinia-takeout-bloomberg
Congrats to posters who own AUPH!
study, Mr. Kane is not a "quick on his feet" thinker, like a slightly younger version of JT.
styles, I don't see how pining at $5 is helping PFE.
ilt, I wish you are right:
https://www.fiercepharma.com/pharma/post-jpm-buzz-names-pfizer-biogen-as-potential-dealmakers
Novartis’ inclisiran should cost between $3,600 and $6,000 a year to be cost-effective, ICER said in a recent report.
https://www.fiercepharma.com/pharma/icer-outlines-cost-effective-price-range-for-pcsk9-cholesterol-drug-inclisiran-should
https://thesocialmedwork.com/leqvio-inclisiran
"not the same degree of overlap as per the GSK/Teva case"? Kiwi, do you know the "degree of overlap in the GSK/Teva case"?
"Settlement could be a way of restoring 6 trig patents to OB as valid"? I believe Judge Du needs to sign off on this which she might not want to do willingly as she had already ruled those patents being invalid in her court.
north, what about Dr. Reddy?
What were these guys/gals discussing?
Our distinguished group of experts, recognized leaders in their respective fields, have been meeting via Zoom to refine their multispecialty practice recommendations @MkosiborodMD @ErinMichos @BudoffMd @deboerih @DLBHATTMD @zbloomgarden @CBallantyneMD @yhandelsmanmd #DCRMDallas pic.twitter.com/eAPfEDC1U4
— DCMInstitute ⚕️ (@DCMinstitute) October 19, 2021
"Get the label corrected"? You sounded like as long as Hikma corrected the gV label, it would no longer infringe. In reality, gV will continue to steal market share as long as it continues to exist because our healthcare system is designed to let generic drugs prosper over branded drugs.
GL takes away more V market share than gV which is under limited supply so not an immediate threat currently.